Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.

TitlePharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
Publication TypeJournal Article
Year of Publication2006
AuthorsHaas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB
Corporate AuthorsAdult AIDS Clinical Trials Group
JournalClin Infect Dis
Volume43
Issue6
Pagination783-6
Date Published2006 Sep 15
ISSN1537-6591
KeywordsAdult, Anti-HIV Agents, Aryl Hydrocarbon Hydroxylases, Case-Control Studies, Cytochrome P-450 CYP2B6, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System, Drug-Induced Liver Injury, Female, Gene Frequency, Genes, MDR, Genotype, HIV Infections, HIV-1, Humans, Liver, Liver Diseases, Male, Nevirapine, Oxidoreductases, N-Demethylating, Polymorphism, Genetic, Randomized Controlled Trials as Topic, Reverse Transcriptase Inhibitors, South Africa
Abstract

Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016).

DOI10.1086/507097
Alternate JournalClin. Infect. Dis.
PubMed ID16912957
Grant List5U01AI025879 / AI / NIAID NIH HHS / United States
AI01744 / AI / NIAID NIH HHS / United States
AI062563 / AI / NIAID NIH HHS / United States
AI139156 / AI / NIAID NIH HHS / United States
AI38855 / AI / NIAID NIH HHS / United States
AI38858 / AI / NIAID NIH HHS / United States
AI46339 / AI / NIAID NIH HHS / United States
AI54999 / AI / NIAID NIH HHS / United States
GM31304 / GM / NIGMS NIH HHS / United States
HL65962 / HL / NHLBI NIH HHS / United States
RR000095 / RR / NCRR NIH HHS / United States